{"name":"Priovant Therapeutics, Inc.","slug":"priovant-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Brepocitinib PO QD","genericName":"Brepocitinib PO QD","slug":"brepocitinib-po-qd","indication":"Systemic lupus erythematosus (SLE)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo PO QD","genericName":"Placebo PO QD","slug":"placebo-po-qd","indication":"Clinical trial control arm (specific indication depends on the trial protocol)","status":"phase_3"}]}],"pipeline":[{"name":"Brepocitinib PO QD","genericName":"Brepocitinib PO QD","slug":"brepocitinib-po-qd","phase":"phase_3","mechanism":"Brepocitinib is a dual JAK1/TYK2 inhibitor that suppresses inflammatory signaling pathways to reduce immune-mediated tissue damage.","indications":["Systemic lupus erythematosus (SLE)","Ulcerative colitis"],"catalyst":""},{"name":"Placebo PO QD","genericName":"Placebo PO QD","slug":"placebo-po-qd","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect.","indications":["Clinical trial control arm (specific indication depends on the trial protocol)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOTHNDR2RoWGUwU3lJeHRocVBKaW5WQ09zM2xwWEQzS1JTMndGcFhUcDV0OUpsNTBycEgwVUY3YUJjZ01EOEJJOXdzaER6RF9yQncwc2txQmlGUnktdXBzNXFWVFhpREthbmlabF9vd0JCYTdyYkJnTUxaNkFsbl9tOGt0Qko4TWRmbjh0QnhQa1AtVkRESktTR2lR?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market - openPR.com","headline":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOX3dYM1MydllBNnp3S2gzNGp5Z1ZSTjRZa1ZuZkdCS3M2dXFlRkQ4VFJzZnpmZXFIMGRJZV8tSl9UUWZibXA2ZTlFUExzX0h4bUI5ajlhaDc5bGx4dmFKMVBLcE5lUmZBaWZDMWtSVGRlQ3Q2SV9RNHFpQUd3bVhfdDJMR0c5TDBxd011ak1kN0VxbGtnY2dkM3ZVVWU2RTdNTFE?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Segment Evaluation and Major Growth Areas in the Alopecia Areata Market - openPR.com","headline":"Segment Evaluation and Major Growth Areas in the Alopecia Areata Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNLWFCS3l3bnFZTjJzdHM5YmxOUVRmWmJsWHZ3OVhkQWY0WHhRM29xcnBlWG90RXRTV1ZtT2xDNllwdDl0aWY5czFIVlJYZ01BQUNpblBUeHRJYlN6Mzc1cDNYY3otaG1Hc2pPSWJYYzZpVXl3NVBvLUZwVTNxd0otZUhiTE9nWHVPbEl4NzBYMHZPTVRoUXp3REctSExBcDJSMG9ya2hLRkI2RlVNdzNCckpSUngxbmlpSmRkdENScHR3d1FTTUNvaklJQXBUTG4wSUdwRHgwYUs5bzFNQm5LR0xzVXVUV1BTYWpMSnNtdUpqVlpUNGxYbXBueU12d0U1RmVKdDJfaHZpUWZYT052S0lYWGZGaC1k?oc=5","date":"2026-03-03","type":"regulatory","source":"GlobeNewswire","summary":"Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis - GlobeNewswire","headline":"Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQRFRVWFhMRmJURTJsdHREeVk5RXVHOTYzbEZBSGZ6M0Y5c2hhNDMxWmpVRHplUUI1NlNZSzRjRHdpakp0cm1NRktOOG15VnRVM29wOFdaUDk0b2dtVmtEYXpaX0Vud21jbDhYc24wZU15VEdJY0w0N1FCYzN4dmJBQzJhV0dBRW9LUzNWX25OLWlXV2p4TTNhNUVfeTJQOU9Pb2VmLUJpV1o?oc=5","date":"2026-02-09","type":"pipeline","source":"The Business Journals","summary":"Pfizer-backed firm advances potential billion-dollar drug for rare skin disease - The Business Journals","headline":"Pfizer-backed firm advances potential billion-dollar drug for rare skin disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQNFVNZzBXZFQ5U094U2hWWGRZeC1BbGNOZUNEd2ZkUmhpbDhfRkp0aWNiZGlZR29CN2ZOTC1RVWIyZUE0UHF0LVZlazJKSnZkY1VsRXFQMlpVeXQ5RkpYWTMtOEZmd0drWGM0bjlxT0NnMVI2dVJjamZ1NEI2RjkydllvVG10XzBleHZEUFFla3FrRnRkekRNVGw2a1A3NXNESEVSM0VnQ1dPbVNtYldrVkFNU3BYOFR1VWZWUzFB?oc=5","date":"2026-02-08","type":"trial","source":"MedCity News","summary":"Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed From Pfizer - MedCity News","headline":"Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed From Pfizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE84NmsxdFpHaEVYVEw5ZXhCT0c5V0ZyTWt4b2dCV0o0LUhEV3FObjBNWnpWTVNhaXZSTU0zQi1SSEl6RHJIbkYwc0ZtV1JLMklDWm1z?oc=5","date":"2026-02-06","type":"pipeline","source":"FirstWord Pharma","summary":"Priovant posts mid-stage success for brepocitinib in cutaneous sarcoidosis - FirstWord Pharma","headline":"Priovant posts mid-stage success for brepocitinib in cutaneous sarcoidosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQWmViUGN6YUVOWi1TV3FGdjRaYnY1UnZjVkxSQTloUGl3MGJVTTJNc3hGcXluTlVZQmdwQ2lvbkZiX0R5UnF0MTMtQ0dGS19WLTU2OFJIblZUSmN4TnpiS3c1LXFod2RRMC1Sa3p1ckw4UzFyQVEyVXBsSDFCSHdZdWNtcnNYNHN3N0g0Vzk1MUFpVnNyUy1jaUtVTlNZazRl?oc=5","date":"2025-09-17","type":"trial","source":"BioWorld News","summary":"Roivant, Priovant plan NDA on positive dermatomyositis data - BioWorld News","headline":"Roivant, Priovant plan NDA on positive dermatomyositis data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNWUNLbWhqczI0TjVtWkIzT1FSYnZnMVA3SlNLNW5wdXFkQUhJTTZyQ0pONXBXdW50ZDFvREdReFEzQjlOeFk4UjBnZHFaOHYzV1V6d3Y3UDMtUnN6Ym5rejZlYTZSOS1fSmY4OEdBZGJ3cl82cFVQbU9oY256bS1FSUZKeGJqbFhnb0JycVhyV2dYUUxIU01V?oc=5","date":"2025-09-17","type":"trial","source":"Fierce Biotech","summary":"Roivant reports phase 3 autoimmune win for ex-Pfizer asset - Fierce Biotech","headline":"Roivant reports phase 3 autoimmune win for ex-Pfizer asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQNnNqOTBTbi1MY1RzdVVVNHRkcTE4VzdJVEV2Um5xS1pJYWN3TWs5cy1YanZIbGJ6UTZiNjRtZVhhZXJwUjhLYWdUZXpnal9EeTdnWE5Cb0V4RlN4UE4tMTVKNDBzOXpFRFhlNUJMeDY5Y2pSTGx3ZHBoNF9Hd09zd1ctZ3JGVl94OTlfcFFrUk14S0w1Wkk0?oc=5","date":"2025-09-17","type":"trial","source":"BioPharma Dive","summary":"Roivant pill succeeds in rare inflammatory disease trial - BioPharma Dive","headline":"Roivant pill succeeds in rare inflammatory disease trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5yUmlWdTZ1VE1la1Q0WEFqOHJ3VDVnYkNnTzItek5sR29kSU43ODEwQjlGZUZaUDM0V0NxZlFfYnlYZjFJMWpZaDJUckV6cHJMWE9r?oc=5","date":"2025-09-17","type":"trial","source":"FirstWord Pharma","summary":"Priovant scores Phase III study success for brepocitinib in dermatomyositis - FirstWord Pharma","headline":"Priovant scores Phase III study success for brepocitinib in dermatomyositis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNaUNkWFJrTENwNWpXRzNNYzMxeV9oQXNYNHl3VFFKUENqc0JMdDdpTy1tY2NqMHU4UWRIVlpzUV9CNFhyLXRfNUZaaExMTnFUcklXVGo4dnNHNy02cHVYemc1VHN6R2NuNGFTYlZCSHF3bXQ2blhDNlNmazlrVE0wR0N6aHVtbkxxcnhsTkwzd1k2R3JDVk1DekZOWQ?oc=5","date":"2022-07-25","type":"pipeline","source":"Pharma Voice","summary":"Behind Pfizer’s new quest to target a ‘transformation’ in pharma - Pharma Voice","headline":"Behind Pfizer’s new quest to target a ‘transformation’ in pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNbG1yR01QNS1KYTZtUGdESExIZmpwSGZUUFg3cFp4SnI1emFjX2FwaWZHRmNiYndlQmIyXzVyQUx0SER3bE1mYjdHQU1LcVpESENpRV9JeTAzcjQ5N09jbndiQkthUTJHOUkzNE5aSXpZZ193aGpfWnR4aE92bVpramRaQ29iX2tFQlNjV2xyOEo1ZE05d2pZ?oc=5","date":"2022-06-28","type":"pipeline","source":"The Pharma Letter","summary":"Roivant and Pfizer unveil Priovant Therapeutics - The Pharma Letter","headline":"Roivant and Pfizer unveil Priovant Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}